Abstract: Systems and methods include reception of a first request to generate an image comprising a first prompt, determination of a first job sequence for the first request, storage of metadata comprising an identifier of the request, the first job sequence and a first status of a first job, generation of a first message comprising the identifier, the first prompt and the first job sequence, storage of the first message in a first processing queue, retrieval of the first message by a first service, prompting of an image generation model to generate a first image based on the prompt, storage of the first image in a blob store, storage of a URL associated with the image in the cache, update of the first status to a second status, and return of the URL.

Abstract: Systems and methods include reception of a first request to generate an image comprising a first prompt, determination of a first job sequence for the first request, storage of metadata comprising an identifier of the request, the first job sequence and a first status of a first job, generation of a first message comprising the identifier, the first prompt and the first job sequence, storage of the first message in a first processing queue, retrieval of the first message by a first service, prompting of an image generation model to generate a first image based on the prompt, storage of the first image in a blob store, storage of a URL associated with the image in the cache, update of the first status to a second status, and return of the URL.

Abstract: Systems include reception of metadata of a Web3 asset at a Web interface, storage of the metadata in a database in association with a tenant identifier, transmission of one or more instructions to execute a process to record the Web3 asset to a distributed ledger, updating, during execution of the process, of a current state of the process in a record of the database associated with the tenant identifier, determination of an error associated with execution of the process, determination of an error notification comprising a retry option based on the current state of the process in the record, reception of a selection of the retry option, and, in response to receipt of the selection, resume execution of the process at a state immediately prior to the current state of the process in the record.

Abstract: A water closet carrier assembly for mounting a water closet having an outlet to a plurality of wall members includes a faceplate having a central portion extending in a widthwise direction between a first side and a second side, and a water closet outlet opening configured to align with an outlet of the water closet, a first side portion coupled to the central portion at the first side, the first side portion including a first side portion mounting aperture, and a second side portion coupled to the central portion at the second side, the second side portion including a second side portion mounting aperture. The water closet carrier assembly also includes first and second fasteners configured to couple the first and second side portions, respectively, to first and second wall members, respectively, of the plurality of wall members. The faceplate is supported solely by the plurality of wall members.

Abstract: The invention relates generally to peptide biomarkers with specific ionization characteristics to directly quantify one or more target HPPD proteins in biological samples, including crop plant samples, by liquid chromatography coupled tandem mass spectrometry multiple reaction monitoring (MRM). The peptide biomarkers in combination with MRM-based methods may be used to quantify a single target protein or multiple target proteins within a crop plant, such as maize, utilizing selected peptide biomarkers either alone or in combination. The present disclosure allows for broad based, reliable quantitation in different biological matrices, including plant matrices. Also provided are different peptide biomarker combinations that can be used to perform the methods of the invention.

Abstract: Devices for treating a bone and methods of inserting such devices into a bone are disclosed. A device for treating a bone may include a flexible tube, a stiffening mechanism and an actuator. The flexible tube has a distal end and a proximal end. The stiffening mechanism within the flexible tube is configured to cause the flexible tube to become rigid. The actuator is configured to cause the stiffening mechanism to cause the flexible tube to become rigid in response to the actuator being actuated.

Abstract: Techniques are provided for an isolated test environment for ransomware analysis. One or more enterprise applications are assigned to one or more server systems to be provisioned in an isolated test environment. An enterprise replica is generated in the isolated test environment by provisioning the one or more server systems and deploying the one or more enterprise applications on the one or more server systems. A kernel monitoring component is deployed on the one or more server systems in the isolated test environment. The kernel monitoring component is configured to generate kernel telemetry data for a plurality of system calls initiated by processes executing on the one or more server systems. A selected ransomware variant is deployed in the isolated test environment. An effect of the selected ransomware variant on the enterprise replica is determined based on analyzing the kernel telemetry data.

Abstract: Techniques are provided for ransomware defense and analysis based on kernel telemetry data. System calls initiated by processes executing on a computer system are monitored. Kernel telemetry data is generated for a plurality of system calls, the kernel telemetry data associating, for each system call of the plurality of system calls, a process invoking the system call, an operation type of the system call, and a target of the system call. The kernel telemetry data is analyzed. Based on analyzing the kernel telemetry data, it is determined that a particular process executed under control of a ransomware agent. In response to determining that the particular process executed under the control of the ransomware agent, one or more response measures are initiated.

Abstract: Systems include reception of a request at a Web server to create a Web3 asset on a Web3 database, the Web3 asset associated with metadata of one or more attributes and, in response to the received request, generation of an operation to create the Web3 asset on the Web3 database and transmission of the operation to the Web3 database. An instruction is received at the Web server to assign the Web3 asset to a user, an identifier of the user is stored in association with an identifier of the Web3 asset and the metadata, a user request to claim a benefit of one of the attributes is received at the Web server, it is determined at the Web server that the user is associated with Web3 asset based on the stored user identifier, and the benefit is provided to the user in response to the determination.

Abstract: Systems include reception of a request at a Web server to create a Web3 asset on a Web3 database, the request identifying metadata and data associated with the Web3 asset. In response to the received request, an identifier of the Web3 asset is stored in a database table in association with the metadata and an identifier of a tenant, the data associated with the Web3 asset is stored in a blob store, an encrypted operation is generated to create the Web3 asset on the Web3 database, where the encrypted operation encrypted by a private key associated with the identifier of the tenant, and the encrypted operation is transmitted to the Web3 database.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Abstract: Inorganic binders comprising silicon or phosphorus have been discovered that offer advantages for use in rechargeable alkali metal ion battery anodes. These improved anodes are less hydrophilic and not subject to the deformation that can occur in conventional anodes from water absorption even at dry room levels. However, the performance characteristics in batteries is comparable to or even better than that obtained from conventional anodes. Also advantageously, these anodes can be prepared from aqueous slurries.

Abstract: The invention relates generally to synthetic non-antibody protein scaffolds (synNAPS) that differentially detect or quantitate a target insecticidal protein in a complex biological matrix comprising the target protein and a non-target insecticidal protein and to methods of using the synNAPS in immunoassays, and more particularly to monoclonal antibodies and immunoassays for the differential detection and quantitation of a wild-type crystal protein, such as a wild-type-Cry1Ab, from Bacillus thuringiensis and hybrid crystal proteins, which comprise all or a significant portion of the wild-type Cry protein in complex biological samples comprising both the wild-type Cry protein and one or more of the hybrid Cry proteins.

Abstract: The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.